RevitalizeMe
Hyperbaric Oxygen & Wound Care
3200 Cabaret Trail S., Suite 3 | Saginaw, MI 48603
(989) 320-4434 | HyperbaricWoundCare.com
(989) 320-4434 | HyperbaricWoundCare.com
Clinical Evidence Summary
Radiation Cystitis (Hemorrhagic) & HBOT
FDA & CMS Approved
| Medicare & Medicaid Covered
80%
Response rate in patients with radiation-induced hemorrhagic cystitis
Chong et al., J Urology 2005
20–40
HBOT sessions — standard CMS-covered course for radiation cystitis
CMS Coverage Policy NCD 20.29
10–15%
Of pelvic radiation patients develop significant hemorrhagic cystitis
Clinical Epidemiology Data
Clinical Overview
Radiation cystitis is a debilitating late complication of pelvic radiotherapy — occurring in 10–15% of patients treated for prostate, cervical, bladder, and colorectal cancers. Radiation obliterates submucosal vasculature, producing progressive ischemia, mucosal atrophy, and fragile neovascularization prone to hemorrhage. When conservative measures fail, HBOT is the most effective treatment — directly addressing the underlying hypoxic injury through neoangiogenesis of the bladder wall.
Key Published Evidence
Journal of Urology — Retrospective Study
Chong et al. reported that 80% of patients with grade II–IV hemorrhagic cystitis achieved complete or partial cessation of hematuria following HBOT, with durable response at follow-up. HBOT was described as the primary treatment of choice when intravesical therapy fails.
Chong KT, et al. J Urol. 2005;173(6):1944–1947.
BJU International — Systematic Review
Del Pizzo et al. reviewed outcomes across multiple studies and found HBOT produced complete resolution in 76–92% of refractory radiation cystitis cases, with significant reduction in transfusion requirements and cystoscopic intervention rates.
Del Pizzo JJ, et al. BJU Int. 1998;82(4):511–515.
Medicare Coverage — NCD 20.29
Hemorrhagic radiation cystitis is a CMS-covered HBOT indication. Medicare and Medicaid cover 20–40 sessions when conservative measures have been exhausted. Most major commercial payors follow CMS coverage criteria.
CMS National Coverage Determination 20.29
How HBOT Works
1
Promotes neoangiogenesis in radiation-damaged bladder submucosa
2
Restores mucosal integrity — reducing fragile vessel rupture and hemorrhage
3
Reverses tissue hypoxia caused by radiation-obliterated vasculature
4
Reduces inflammatory response in the bladder wall
Ideal Referral Candidate
History of pelvic radiation for prostate, cervical, bladder, or colorectal cancer
Gross hematuria requiring transfusion or repeated cystoscopy
Failed conservative measures (fulguration, intravesical alum, etc.)
Recurrent UTI or bladder pain associated with radiation damage
Standard HBOT Protocol
Pressure
2.0–2.4 ATA
Duration
90 min/session
Sessions
20–40 dives
Setting
Outpatient